The fast pandemic of COVID-19 is shining a light on a much slower silent pandemic, that of metabolic disease; prediabetes, diabetes, clinical obesity and nonalcoholic fatty liver disease.
With 1 in 2 people struggling with metabolic disease among US adults, our whitepaper urgently examines the inconvenient reality of the COVID-19 virus on the largest, most vulnerable population.
Data from the U.S. Centers for Disease Control and Prevention shows that people with diabetes are most at risk of hospitalization and 40% of all deaths were related to the condition.
For employers and payers, we explore why it’s time to offer your employees and patient members a precision medicine solution that enables a path to remission for metabolic disease.
